Atrys increases its revenues to 117.1 million until September, 9.7% more, thanks to the boost from oncology and nuclear medicine

Atrys increases revenue, Ebitda and cash up to September, reduces debt and strengthens oncology and nuclear medicine while maintaining its targets for 2026.

fotonoticia 20261116101621 1920

fotonoticia 20261116101621 1920

Add DEMÓCRATA to Google

Ask FREN

Published

3 minutes

Most read

Elecciones 29N · Encuestas

La media de las encuestas

Media a 16 de noviembre de 2026 · 16 institutos

  • PP31,4 %
  • PSOE27,0 %
  • Vox19,0 %
  • Frente Amplio6,2 %
  • ERC2,5 %
01020304050ene 2024jul 2024ene 2025jul 2025ene 2026jul 2026

Media del último estudio de cada instituto en 30 días y su evolución semanal desde el 23J. Partidos con al menos un 2 %.

Todas las encuestas

Elecciones generales del 29 de noviembre · Demócrata

ELECCIONES 29N

¿Cuál es tu pronóstico? 29N

Reparte los 350 escaños del Congreso como creas que quedarán el 29 de noviembre. Puedes cambiar tu pronóstico hasta que cierren los colegios.

0 de 350 escaños

PP
PSOE
Vox
Frente Amplio
ERC
Junts
EH Bildu
PNV
Más partidos
Podemos
BNG
SALF
CC
UPN
Adelante
Aliança
Otros

Protegido por reCAPTCHA de Google: privacidad y condiciones

Pronóstico de DemócrataParticipación abierta, no es una encuesta

Atrys Health reached revenue of 117.1 million euros in the first nine months of the year, which represents an advance of 9.7% compared to the same period of the previous fiscal year, supported by the expansion of the oncology and nuclear medicine areas, as the company detailed in a statement released this Monday.

Gross margin stood at 49 million euros, 6.5% higher, while gross operating result (Ebitda) rose to 14.2 million, representing an increase of 18.5% compared with the previous year, with an Ebitda margin of 12.2%, versus the 11.3% recorded twelve months earlier.

If the accounting effects associated with the activation of research and development (R&D) expenses are left aside, organic Ebitda records growth of 40.3%.

Strong improvement in operating cash flow and cost cut

This progress, together with "greater investment discipline," resulted in higher cash generation, with operating cash flow of 11.3 million euros, 152.6% higher. The accounts also reflect the "efficiency improvements" derived from the new organizational model implemented in 2026, designed to simplify the structure and strengthen management control.

The initiatives that have been launched have made it possible to reduce corporate personnel and operating expenses by 15.1% and 23.3%, respectively. In this way, the company emphasizes that it closes the first nine months of 2026 with a "solid" financial structure.

After the divestment of its subsidiary Aspy Global Services, the group’s prevention division, sold to Grupo Echevarne for 145 million euros and whose transaction was completed in January, net financial debt was reduced to 37.5 million at the end of September, 78.1% less than at the end of 2025.

Savings in financial expenses and reordering of debt

"Financial optimization also enabled savings of 6.3 million euros in financial expenses compared with the same period of the previous year," the company noted, adding that it continues to move forward with the reordering of its debt in order to align it with the needs of its strategic plan 2026-2028.

Atrys’ CEO, Marian Isach, highlighted that "these results reflect the progress in the execution of the strategy and the commitment to improving profitability, cash generation, and strengthening care capacity".

It has also stressed that "the growth of our strategic areas and the efficiency improvements we are implementing allow us to tackle the final stretch of the year with confidence in meeting our objectives, while keeping the focus on providing specialized, high-quality healthcare care".

Oncology and nuclear medicine drive growth by area

As for business lines, oncology has been reaffirmed as one of Atrys's main growth engines, with a 22.5% increase in revenue and a 17.1% increase in EBITDA. In turn, nuclear medicine increased its billing by 10% and boosted its EBITDA by 157.4%, especially due to the strong performance of activity in Portugal.

The imaging diagnostics division also recorded a favorable trend, with a 7.2% increase in revenue. In Spain, imaging diagnostics advances (+15.4%) and oncology (+5.9%) stand out, together with the positive performance of nuclear medicine, which raised its revenues by 6.5% and its EBITDA by 56.4%.

Portugal consolidated the recovery of its profitability, with a 5.7% increase in the business figure and an EBITDA 6.8 times higher than that of the same period in the previous year, reaching 2.4 million euros, thanks to the management measures applied and to the boost in nuclear medicine, whose revenues grew by 11.9%.

At the same time, Latin America increased its revenues by 28.2%, driven notably by Mexico, where billing advanced by 131.9% and EBITDA by 216.5%, supported by the consolidation of the medical oncology business.

Targets for 2026: more revenue, EBITDA and cash

After the performance of the first nine months of the year, Atrys has reiterated that it maintains its goals for the full year 2026, which involve reaching a turnover of 156.5 million euros, 11% higher, and a reported EBITDA of 20.5 million euros, 34% more.

In addition, the company expects to achieve an operating cash flow of 13.5 million euros, which would represent a 125% increase compared with the previous year.